Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AL003 · 1 trial · 2 indications
Incidence of adverse events during the treatment and follow up periods through out the study.
| Arm | Type | Description |
|---|---|---|
| AL003 by intravenous (IV) infusion | ACTIVE_COMPARATOR | Single-doses of AL003 in dose-escalating cohorts Multiple doses of AL003 in single cohort |
| Placebo by intravenous (IV) infusion | PLACEBO_COMPARATOR | Matching saline solution will be administered for placebo subjects |
| Name | Type | Description |
|---|---|---|
| AL003 | BIOLOGICAL | Single-doses of AL003 in dose-escalating cohorts Multiple doses of AL003 in a single cohort |
| Saline Solution | OTHER | Saline Solution will be administered as a single infusion for each dose escalation cohort in a ratio of 6 active and 2 placebo and as multiple infusions in the single cohort in a ratio of 10 active and 2 placebo |
Inclusion Criteria: 1. Total body weight between 50 and 120 kg, inclusive 2. Clinical laboratory evaluations (including chemistry panel fasted \[at least 8 hours\], complete blood count (CBC), and urine analysis) within the reference range for the test laboratory, unless deemed not clinically signi...
AL003 is an investigational monoclonal antibody being developed by Alector, Inc. for potential use in neurology. It is currently in Phase 1 clinical development. The drug has been studied in a first-in-human trial that included healthy volunteers and participants with Alzheimer's disease.
AL003 is being studied for use in Alzheimer's disease. A Phase 1 clinical trial evaluated the drug in healthy volunteers and in participants with Alzheimer's disease to assess its safety and tolerability. The drug is still in early clinical development and is not yet approved for any use.
AL003 is a monoclonal antibody, a type of biologic drug designed to bind to a specific target in the body. However, the specific molecular target of AL003 has not been disclosed in available information. The drug is being investigated for its potential role in treating neurological conditions.
AL003 is being developed by Alector, Inc., a biopharmaceutical company. Alector is publicly traded under the ticker symbol ALEC. The company is focused on developing therapies for neurodegenerative diseases.
AL003 is in Phase 1 clinical development. A Phase 1 first-in-human study (NCT03822208) has been completed. This early-stage trial was designed to evaluate the safety and tolerability of the drug in healthy volunteers and in people with Alzheimer's disease.
AL003 has one completed Phase 1 clinical trial, registered as NCT03822208, titled "First in Human Study for Safety and Tolerability of AL003." The trial enrolled 54 participants, including healthy volunteers and individuals with Alzheimer's disease, and was conducted in the United States and Australia.